Water for injection sits at the heart of sterile injectable manufacturing — yet it’s often treated as a background utility.
As biologics, vaccines, and high-value injectables drive demand, WFI has become a strategic constraint, with regulatory, cost, and operational implications that can delay or derail programs.
Download our free article to explore why WFI is no longer an afterthought, when outsourcing makes sense, and what to consider when choosing a CDMO partner.
